Findings

What do systematic reviews say?

1,268 questions · 1,343 findings · 197 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 317 · 23.6%GRADE not reported 189 · 14.1%Very low 356 · 26.5%Low 271 · 20.2%Moderate 173 · 12.9%High 37 · 2.8%

Neuroprotection vs control

Quality of life measures · people with open‐angle glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Neuroprotection for treatment of glaucoma in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neuroprotection vs control

Cost / economic data · people with open‐angle glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Neuroprotection for treatment of glaucoma in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pathogen‐reduced platelets vs standard platelets

Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ · thrombocytopenia

Pathogen‐reduced platelets may leads to higher number of participants with 'any bleeding' event(s) (WHO grade 1 to… compared with standard platelets (low certainty).

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
RR 1.09 [1.02, 1.15]
5 studies · 1085 participants
Low

Pathogen‐reduced platelets vs standard platelets

Number of participants with clinically significant bleeding · thrombocytopenia

Pathogen‐reduced platelets showed no clear difference in number of participants with 'clinically significant' bleeding… compared with standard platelets (moderate certainty).

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
RR 1.1 [0.97, 1.25]
5 studies · 1392 participants
Moderate

Pathogen‐reduced platelets vs standard platelets

Number of participants with 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ · thrombocytopenia

Pathogen‐reduced platelets showed no clear difference in number of participants with 'severe' bleeding event(s) (WHO grade ≥… compared with standard platelets (moderate certainty).

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
RR 1.24 [0.76, 2.02]
6 studies · 1495 participants
Moderate

Pathogen‐reduced platelets vs standard platelets

All‐cause mortality · thrombocytopenia

Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
RR 0.81 [0.5, 1.29]
6 studies · 1509 participants
Moderate

Pathogen‐reduced platelets vs standard platelets

Number of participants with a serious adverse event · thrombocytopenia

Pathogen‐reduced platelets showed no clear difference in number of participants with a serious adverse event compared with standard platelets (moderate certainty).

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
RR 1.09 [0.88, 1.35]
7 studies · 1340 participants
Moderate

Pathogen‐reduced platelets vs standard platelets

Number of participants experiencing platelet refractoriness · thrombocytopenia

Pathogen‐reduced platelets leads to higher number of participants experiencing platelet refractoriness compared with standard platelets (high certainty).

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
RR 2.94 [2.08, 4.16]
7 studies · 1525 participants
High

Pathogen‐reduced platelets vs standard platelets

Number of platelet transfusions per participant up to 30 days from study entry · thrombocytopenia

1 finding from 1 review

Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1509 participants
High

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Repeated need for rapid tranquillisation ‐ more than 3 injections · patients with psychosis‐induced aggression or agitation

It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more than 3 injections compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
RR 2.54 [1.19, 5.46]
1 study · 70 participants
Very low

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Global outcome ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Tremor · patients with psychosis‐induced aggression or agitation

It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ tremor by 7 days compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
RR 4.16 [0.93, 18.62]
1 study · 70 participants
Very low

HALOPERIDOL vs OTHER ANTIPSYCHOTIC: j. ZUCLOPENTHIXOL ACETATE

Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation

The review found no eligible studies for this question.

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombopoietin mimetics vs placebo

Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 282 participants
GRADE not reported

Thrombopoietin mimetics vs placebo

Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.97 [0.73, 1.27]
6 studies · 746 participants
Low

Thrombopoietin mimetics vs placebo

Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia

It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 1.02 [0.59, 1.77]
5 studies · 372 participants
Very low

Thrombopoietin mimetics vs placebo

Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.92 [0.86, 0.98]
5 studies · 390 participants
Moderate

Thrombopoietin mimetics vs placebo

Blood transfusion requirements · Adult patients with myelodysplastic syndromes and thrombocytopenia

Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).

1 finding from 1 review

Thrombopoietin mimetics for patients with myelodysplastic syndromes 2017 · Cochrane Headline outcomes only
RR 0.83 [0.66, 1.05]
4 studies · 358 participants
Low